Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:169
Name neuroendocrine tumor
Definition An endocrine gland cancer that has_material_basis_in neuroendocrine cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer neuroendocrine tumor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
RB1 loss Sirolimus neuroendocrine tumor sensitive detail...
CDKN2A loss ZK 304709 neuroendocrine tumor sensitive detail...
BRAF V600E Dabrafenib + Trametinib neuroendocrine tumor predicted - sensitive detail...
BRAF V600E Trametinib + Vemurafenib neuroendocrine tumor predicted - sensitive detail...
MLH1 negative Pembrolizumab neuroendocrine tumor sensitive detail...
MSH6 negative Pembrolizumab neuroendocrine tumor sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00926640 Phase I Belinostat + Cisplatin + Etoposide A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers Completed USA 0
NCT01177397 Phase Ib/II Onatasertib Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Completed USA | FRA | ESP 1
NCT01466036 Phase II Cabozantinib Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Active, not recruiting USA 0
NCT01841736 Phase II Pazopanib Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors Active, not recruiting USA | CAN 0
NCT02063958 Phase I SNX-5422 Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors Completed USA 0
NCT02205515 Phase Ib/II Everolimus An Open Label, Single-Centre, Phase II Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis Unknown status CAN 0
NCT02250885 Phase II Selinexor KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors Completed USA 0
NCT02259725 Phase II Regorafenib Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Completed USA 0
NCT02279433 Phase I Taletrectinib A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b Completed USA 0
NCT02315625 Phase II Everolimus Sunitinib Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery Terminated USA 0
NCT02399215 Phase II Nintedanib Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Active, not recruiting USA 0
NCT02402920 Phase I Carboplatin + Etoposide + Pembrolizumab Cisplatin Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer Active, not recruiting USA 0
NCT02420691 Phase II Ribociclib LEE011 in Neuroendocrine Tumors of Foregut Origin Completed USA 0
NCT02454972 Phase II Lurbinectedin Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors Completed USA | ITA | FRA | ESP | DEU | BEL 3
NCT02487095 Phase Ib/II Berzosertib Topotecan Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer Active, not recruiting USA 0
NCT02489903 Phase II Etoposide RRx-001 Carboplatin Cisplatin Nab-paclitaxel RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens Active, not recruiting USA 0
NCT02628067 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting USA | ITA | FRA | ESP | DEU | CAN 14
NCT02754297 Phase II lutetium Lu 177 dotatate Personalized PRRT of Neuroendocrine Tumors (P-PRRT) Recruiting CAN 0
NCT02795858 Phase II Octreotide + Ramucirumab A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors Active, not recruiting USA 0
NCT02831179 Phase I Capecitabine + Temozolomide + Veliparib Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn 0
NCT02875223 Phase I CC-90011 A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas Recruiting ITA | FRA | ESP 2
NCT02936323 Phase Ib/II PEN-221 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Completed USA 1
NCT02939651 Phase II Pembrolizumab A Study of Pembrolizumab in Patients With Neuroendocrine Tumors Completed USA 0
NCT02955069 Phase II Spartalizumab Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin Completed USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 4
NCT03014297 Phase I Everolimus + Fosbretabulin Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression Terminated USA 0
NCT03034200 Phase II ONC201 Phase 2 Study of ONC201 in Neuroendocrine Tumors Active, not recruiting USA 0
NCT03070301 Phase II Everolimus + Ribociclib A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors Active, not recruiting USA 0
NCT03074513 Phase II Atezolizumab + Bevacizumab Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors Active, not recruiting USA 0
NCT03095274 Phase II Durvalumab Tremelimumab Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (DUNE) Active, not recruiting ESP 0
NCT03211988 Phase II Entinostat Entinostat Neuroendocrine (NE) Tumor Recruiting USA 0
NCT03289741 FDA approved Lanreotide acetate + Octreotide A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide Active, not recruiting USA 0
NCT03290079 Phase II Pembrolizumab Pembrolizumab in Advanced Poorly Differentiated and/or High Grade Neuroendocrine Tumors/Carcinomas Suspended USA 0
NCT03365791 Phase II Ieramilimab Spartalizumab PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies Completed USA 0
NCT03375320 Phase III Cabozantinib Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery Recruiting USA 0
NCT03411915 Phase I XmAb18087 A Study of XmAb18087 in Subjects With NET and GIST Completed USA 0
NCT03420521 Phase II Ipilimumab + Nivolumab Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors Active, not recruiting USA 0
NCT03457948 Phase II Pembrolizumab Pembrolizumab + Yttrium-90 microsphere therapy Pembrolizumab and Liver-Directed Therapy in Treating Patients With Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Liver Metastases Recruiting USA 0
NCT03475953 Phase Ib/II Avelumab + Regorafenib A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) Recruiting FRA 0
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Active, not recruiting USA 0
NCT03950609 Phase II Everolimus + Lenvatinib Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors Recruiting USA 0
NCT03980925 Phase II Carboplatin + Etoposide + Nivolumab Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. Recruiting ESP 0
NCT04197310 Phase II Cabozantinib + Nivolumab Cabozantinib and Nivolumab for Carcinoid Tumors Recruiting USA 0
NCT04234568 Phase I lutetium Lu 177 dotatate + Triapine Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors Recruiting USA 0
NCT04400474 Phase II Atezolizumab + Cabozantinib Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study (CABATEN) Recruiting ESP 0
NCT04412629 Phase II Cabozantinib Cabozantinib in High Grade Neuroendocrine Neoplasms Recruiting USA 0
NCT04427787 Phase II Cabozantinib + Lanreotide acetate A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET (LOLA) Recruiting ITA 0
NCT04450901 Phase I YBL-006 Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors Recruiting 3
NCT04471727 Phase Ib/II HPN328 Study in Patients With Advanced Cancers Associated With Expression of DLL3 Who Have Failed Standard Available Therapy Recruiting USA 0
NCT04524208 Phase II Cabozantinib A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3 (CABONEN) Recruiting DEU 0
NCT04525638 Phase II lutetium Lu 177 dotatate + Nivolumab A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours Recruiting ESP 0
NCT04579679 Phase II Surufatinib Open-Label Surufatinib in European Patients With NET Recruiting USA | ITA | FRA | ESP | DEU 2
NCT04579757 Phase Ib/II Surufatinib + Tislelizumab Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors Recruiting USA 0
NCT04614766 Phase Ib/II 131I-MIBG + lutetium Lu 177 dotatate lutetium Lu 177 dotatate A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors (SPORE-3) Not yet recruiting USA 0
NCT04750954 Phase I lutetium Lu 177 dotatate + Peposertib Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors Recruiting USA 0
NCT04776876 Phase II Retifanlimab + Telotristat etiprate Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome Withdrawn 0
NCT04802174 Phase Ib/II Berzosertib + Lurbinectedin A Phase I/II Trial of Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High Grade Neuroendocrine Cancers Recruiting USA 0
NCT04814732 Expanded access Surufatinib Expanded Access Program of Surufatinib Available USA 0
NCT05000294 Phase Ib/II Atezolizumab + Tivozanib Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types Suspended USA 0
NCT05289856 Phase II Avelumab + Cabozantinib Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3) Recruiting DEU 0